Bicycle Therapeutics (BCYC) Stock Forecast & Price Target

$20.34 -0.02 (-0.10%)

(As of 11/21/2024 ET)

Bicycle Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 9 Analyst Ratings

Sell
0

Hold
2

Buy
7

Based on 9 Wall Street analysts who have issued ratings for Bicycle Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 2 have given a hold rating, and 7 have given a buy rating for BCYC.

Consensus Price Target

$40.13
97.22% Upside

According to the 9 analysts' twelve-month price targets for Bicycle Therapeutics, the average price target is $40.13. The highest price target for BCYC is $60.00, while the lowest price target for BCYC is $25.00. The average price target represents a forecasted upside of 97.22% from the current price of $20.35.

Get the Latest News and Ratings for BCYC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Bicycle Therapeutics and its competitors.

BCYC Analyst Ratings Over Time

Type	Current Forecast 11/23/23 to 11/22/24	1 Month Ago 10/24/23 to 10/23/24	3 Months Ago 8/25/23 to 8/24/24	1 Year Ago 11/23/22 to 11/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$40.13	$44.56	$45.75	$48.57
Forecasted Upside	97.22% Upside	75.97% Upside	104.42% Upside	251.46% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

What This Post-Election Shift Means for Your Investments (Ad)

The election may be over, but its impact on financial markets is only beginning. New trends are emerging, bringing both challenges and opportunities for investors. Many of these changes are flying under the radar, yet they have the potential to reshape the financial landscape for years to come. Understanding how these shifts could affect your wealth—and what steps to take—has never been more important.

Click here now to watch the full briefing and prepare for what's next.

BCYC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BCYC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Bicycle Therapeutics Stock vs. The Competition

Type	Bicycle Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.78	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	97.22% Upside	26,390.75% Upside	8.55% Upside
News Sentiment Rating	Positive News See Recent BCYC News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/8/2024	Stephens 4 of 5 stars	S. Loganathan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$25.00	+1.21%
11/1/2024	Royal Bank of Canada 4 of 5 stars	G. Renza Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$35.00 ➝ $35.00	+48.31%
11/1/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00	+134.59%
10/31/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00	+62.12%
9/16/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Outperform ➝ Market Outperform	$32.00 ➝ $32.00	+23.60%
9/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight
What This Post-Election Shift Means for Your Investments (Ad) The election may be over, but its impact on financial markets is only beginning. New trends are emerging, bringing both challenges and opportunities for investors. Many of these changes are flying under the radar, yet they have the potential to reshape the financial landscape for years to come. Understanding how these shifts could affect your wealth—and what steps to take—has never been more important. Click here now to watch the full briefing and prepare for what's next.
8/7/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$48.00 ➝ $48.00	+110.71%
8/7/2024	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$33.00 ➝ $28.00	+14.85%
2/21/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$60.00	+164.43%
11/3/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $40.00	+168.28%
4/19/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$55.00	+180.76%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:35 AM ET.

BCYC Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Bicycle Therapeutics is $40.13, with a high forecast of $60.00 and a low forecast of $25.00.
: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BCYC shares.
: According to analysts, Bicycle Therapeutics's stock has a predicted upside of 97.22% based on their 12-month stock forecasts.
: Bicycle Therapeutics has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, JMP Securities, Needham & Company LLC, Royal Bank of Canada, and Stephens in the past 90 days.
: Analysts like Bicycle Therapeutics less than other "medical" companies. The consensus rating score for Bicycle Therapeutics is 2.78 while the average consensus rating score for "medical" companies is 2.80. Learn more on how BCYC compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

What This Post-Election Shift Means for Your Investments (Ad)

Click here now to watch the full briefing and prepare for what's next.

This page (NASDAQ:BCYC) was last updated on 11/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicycle Therapeutics (BCYC) Stock Forecast & Price Target